DRESS syndrome primary prevention

Jump to navigation Jump to search

DRESS syndrome Microchapters


Patient Information


Historical Perspective




Differentiating DRESS syndrome from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings


X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

DRESS syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of DRESS syndrome

All Images
syndrome X-ray X-rays
syndrome Ultrasound Echo & Ultrasound
syndrome CT CT Images
syndrome MRI MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on DRESS syndrome

CDC on DRESS syndrome

DRESS syndrome in the news

Blogs on DRESS syndrome

Directions to Hospitals Treating DRESS syndrome

Risk calculators and risk factors for DRESS syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D., Serge Korjian M.D.


There are no established measures for the primary prevention of DRESS syndrome. Primary prevention measures may include slow dose escalation of drugs (e.g. anticonvulsants), genetic counseling, and in vitro impaired detoxification testing.

Primary Prevention

There are no established measures for the primary prevention of DRESS syndrome. Primary prevention measures may include the following:[1]

  • Slow dose escalation of agents known to be associated with DRESS syndrome[2]
  • Genetic counseling to relatives of patients with DRESS syndrome[3]
  • In vitro impaired detoxification testing using lymphocyte toxicity assays among individuals with affected first-degree relatives[3]


  1. Tas S, Simonart T (2003). "Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update". Dermatology. 206 (4): 353–6. doi:69956 Check |doi= value (help). PMID 12771485.
  2. Fitton A, Goa KL (1995). "Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy". Drugs. 50 (4): 691–713. PMID 8536554.
  3. 3.0 3.1 Sullivan JR, Shear NH (2000). "What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?". Br J Dermatol. 142 (2): 205–7. PMID 10730749.

Template:WS Template:WH